Project Details
| Short title | SGNTUC-028 |
|---|---|
| Acronym | HER2CLIMB |
| Status | Active |
| Effective start/end date | 4/08/22 → 23/02/27 |
CTU: A randomized, double-blind, phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for metastatic HER2+ breast cancer (HER2CLIMB-05)
- Sabanathan, Dhanusha (Primary Chief Investigator)
- Chester, Catherine (Clinical Trial Unit Staff)
- Chapman, Nicola (Clinical Trial Unit Staff)
Project: Research